Compare CABR & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABR | PHIO |
|---|---|---|
| Founded | 2020 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9M | 14.6M |
| IPO Year | N/A | 2011 |
| Metric | CABR | PHIO |
|---|---|---|
| Price | $1.16 | $1.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.67 |
| AVG Volume (30 Days) | 98.7K | ★ 235.5K |
| Earning Date | 03-20-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.71 | $0.81 |
| 52 Week High | $1.65 | $4.19 |
| Indicator | CABR | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | 57.95 | 56.15 |
| Support Level | $0.78 | $1.13 |
| Resistance Level | $1.36 | $1.43 |
| Average True Range (ATR) | 0.15 | 0.07 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 67.81 | 72.22 |
Caring Brands Inc is a consumer wellness company that supports health and wellness through research and development. Its product pipeline addresses a range of conditions, including hair loss, eczema, burns, and sexual wellness. The majority of revenue is generated from the sale of OTC and consumer products, as well as licensing royalties.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.